$28.26
+0.71 (+2.58%)
Open$27.53
Previous Close$27.55
Day High$29.10
Day Low$27.53
52W High$54.29
52W Low$11.20
Volume—
Avg Volume28.9K
Market Cap100.90M
P/E Ratio—
EPS$-20.59
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
-3.5% upside
Current
$28.26
$28.26
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.04M | 12.22M | 12.16M |
| Net Income | -80,064,607 | 1.67M | 1.59M |
| Profit Margin | -257.9% | 13.7% | 13.1% |
| EBITDA | -57,589,697 | 2.79M | 3.00M |
| Free Cash Flow | — | 1.30M | 1.27M |
| Rev Growth | — | +12.4% | +20.7% |
| Debt/Equity | — | 0.63 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |